Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Change in Receivables (2021 - 2024)

IDEAYA Biosciences' Change in Receivables history spans 4 years, with the latest figure at -$2000.0 for Q4 2024.

  • For Q4 2024, Change in Receivables rose 99.97% year-over-year to -$2000.0; the TTM value through Sep 2024 reached -$6.7 million, down 305.38%, while the annual FY2023 figure was -$193000.0, 78.36% up from the prior year.
  • Change in Receivables for Q4 2024 was -$2000.0 at IDEAYA Biosciences, down from $19000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $6.5 million in Q3 2023 and bottomed at -$6.7 million in Q4 2023.
  • The 4-year median for Change in Receivables is -$8500.0 (2024), against an average of -$116187.5.
  • The largest YoY upside for Change in Receivables was 1129.64% in 2022 against a maximum downside of 3909.41% in 2022.
  • A 4-year view of Change in Receivables shows it stood at $85000.0 in 2021, then tumbled by 3909.41% to -$3.2 million in 2022, then crashed by 106.45% to -$6.7 million in 2023, then surged by 99.97% to -$2000.0 in 2024.
  • Per Business Quant, the three most recent readings for IDYA's Change in Receivables are -$2000.0 (Q4 2024), $19000.0 (Q3 2024), and -$14000.0 (Q2 2024).